- Trials with a EudraCT protocol (49)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
49 result(s) found for: migraine.
Displaying page 1 of 3.
EudraCT Number: 2017-002866-38 | Sponsor Protocol Number: FM-BOEM | Start Date*: 2018-01-25 | |||||||||||
Sponsor Name:IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO | |||||||||||||
Full Title: Pilot study for the evaluation of the efficacy of OnabotulinumtoxinA in high frequency migraine | |||||||||||||
Medical condition: Migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002470-27 | Sponsor Protocol Number: 3101-312-002 | Start Date*: 2021-05-12 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Allergan Limited | ||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE 3, MULTICENTER, OPEN-LABEL 52-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH CHRONIC OR EPISODI... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) CZ (Trial now transitioned) SE (Completed) HU (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001057-31 | Sponsor Protocol Number: 260221 | Start Date*: 2021-06-28 | |||||||||||
Sponsor Name:Glostrup Hospital, Danish Headache Center | |||||||||||||
Full Title: A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM). | |||||||||||||
Medical condition: Migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004509-30 | Sponsor Protocol Number: 012020 | Start Date*: 2021-05-13 | |||||||||||
Sponsor Name:INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON | |||||||||||||
Full Title: A prospective structural, diffusion and connectomics MRI study on migraine patients treated with Fremanezumab | |||||||||||||
Medical condition: MIGRAINE | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000279-26 | Sponsor Protocol Number: 56536 | Start Date*: 2017-03-07 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Trigeminovascular effects of propranolol in migraine treatment | |||||||||||||
Medical condition: Healthy Volunteers (Migraine) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005256-34 | Sponsor Protocol Number: 38589 | Start Date*: 2012-10-29 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Sumatriptan non-responders: evaluation of a possible biomarker | |||||||||||||
Medical condition: Healthy Volunteers (Migraine) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001288-18 | Sponsor Protocol Number: 16-API-01 | Start Date*: 2019-01-08 | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: ASIC channels and migraine disorders - Proof of concept study on the efficacy of Amiloride in prophylaxis of Migraine with Aura - APAM study | |||||||||||||
Medical condition: Migraine with aura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005239-22 | Sponsor Protocol Number: BHV3000-404 | Start Date*: 2022-06-20 | |||||||||||||||||||||
Sponsor Name:Biohaven Pharmaceuticals Holding Company Limited | |||||||||||||||||||||||
Full Title: A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens | |||||||||||||||||||||||
Medical condition: Acute Migraine (with or without aura) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) AT (Ongoing) SE (Ongoing) IT (Ongoing) PL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003646-33 | Sponsor Protocol Number: 20190008 | Start Date*: 2020-06-24 | |||||||||||
Sponsor Name:Amgen, Inc. | |||||||||||||
Full Title: Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Ph... | |||||||||||||
Medical condition: High frequency episodic migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) PT (Completed) HU (Completed) BG (Completed) CZ (Completed) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003049-40 | Sponsor Protocol Number: 20007A | Start Date*: 2022-07-22 | ||||||||||||||||
Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||
Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in pati... | ||||||||||||||||||
Medical condition: Migraine and medication overuse headache | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) SE (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001175-14 | Sponsor Protocol Number: BHV3000-406 | Start Date*: 2023-04-17 | |||||||||||
Sponsor Name:Biohaven Pharmaceuticals, Inc. | |||||||||||||
Full Title: BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use | |||||||||||||
Medical condition: migraine attacks with or without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) SE (Ongoing) FI (Ongoing) DK (Ongoing) AT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005481-30 | Sponsor Protocol Number: ADX10059-206 | Start Date*: 2009-03-03 | |||||||||||
Sponsor Name:Addex Pharma SA | |||||||||||||
Full Title: A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multicentre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric modu... | |||||||||||||
Medical condition: Migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Ongoing) FR (Ongoing) GB (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017041-58 | Sponsor Protocol Number: MIGRANYA | Start Date*: 2010-03-18 | |||||||||||||||||||||
Sponsor Name:Consorci Sanitari del Maresme | |||||||||||||||||||||||
Full Title: Ensayo clínico exploratorio sobre la eficacia y la seguridad de la osteopatia en el tratamiento preventivo de la migraña | |||||||||||||||||||||||
Medical condition: La migraña es una condición clínica muy prevalente y altamente invalidante que tiene unos importantes costes sociales. Distintos tratamientos farmacológicos han demostrado ser eficaces en la preven... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004096-12 | Sponsor Protocol Number: WHAT!-RCT | Start Date*: 2019-06-03 | |||||||||||
Sponsor Name:LUMC | |||||||||||||
Full Title: Open-label randomized controlled trial for the effects of continuous ethinylestradiol/levonorgestrel (30/150 μg/day) compared with vitamin E (400 IU/day) in the treatment of menstrually-related mig... | |||||||||||||
Medical condition: Migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003386-18 | Sponsor Protocol Number: CandMigIII | Start Date*: 2019-12-18 | |||||||||||
Sponsor Name:Department of Neurology and Clinical Neurophysiology, St Olavs Hospital, Trondheim University hospital | |||||||||||||
Full Title: CandMig III study Candesartan for migraine prevention: A multicentre, binational, triple blind, placebo controlled, parallel group study of two doses of candesartan (8 and 16 mg) | |||||||||||||
Medical condition: Episodic migraine with and without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) EE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001176-34 | Sponsor Protocol Number: BHV3000-407 | Start Date*: 2023-02-20 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: BHV3000-407: A Phase 4, Randomized, Doubleblind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequa... | |||||||||||||
Medical condition: migraine headaches with or without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) IT (Ongoing) FI (Ongoing) DK (Ongoing) AT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002825-22 | Sponsor Protocol Number: PROPUDO | Start Date*: 2011-12-29 |
Sponsor Name:Hospital General Universitario de Alicante | ||
Full Title: Pilot, placebo-controlled, double-blind, randomized, parallel propofol effective in preventing refractory chronic migraine | ||
Medical condition: Refractory chronic migraine | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001883-21 | Sponsor Protocol Number: I5Q-MC-CGAI | Start Date*: 2016-01-18 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study | |||||||||||||
Medical condition: Chronic Migraine Headache | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001979-16 | Sponsor Protocol Number: M21-307 | Start Date*: 2021-11-11 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine | |||||||||||||
Medical condition: Episodic Migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) SE (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001989-15 | Sponsor Protocol Number: TV48125-MH-40142 | Start Date*: 2020-03-27 | ||||||||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of... | ||||||||||||||||||
Medical condition: Migraine and major depressive disorder (MDD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) FR (Completed) FI (Completed) GR (Completed) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.